The estimated Net Worth of Venture Capital Vi, L.P. Ve... is at least 104 百万$ dollars as of 27 December 2019. Venture Ve owns over 389,382 units of Akero Therapeutics Inc stock worth over 93,681,708$ and over the last 5 years Venture sold AKRO stock worth over 10,662,564$.
Venture has made over 4 trades of the Akero Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture sold 389,382 units of AKRO stock worth 9,423,044$ on 27 December 2019.
The largest trade Venture's ever made was buying 400,000 units of Akero Therapeutics Inc stock on 24 June 2019 worth over 6,400,000$. On average, Venture trades about 212,068 units every 47 days since 2019. As of 27 December 2019 Venture still owns at least 3,656,585 units of Akero Therapeutics Inc stock.
You can see the complete history of Venture Ve stock trades at the bottom of the page.
Venture's mailing address filed with the SEC is ONE SANSOME STREET, SUITE 3630, , SAN FRANCISCO, CA, 94104.
Over the last 5 years, insiders at Akero Therapeutics Inc have traded over 146,260,704$ worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth 104,250,550$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Trust Blue Horizon Enterpri...、G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,642,344$. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth 133,600$.
akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.
Akero Therapeutics Inc executives and other stock owners filed with the SEC include: